Torasemide（CAS:56211-40-6)

Torasemide, with CAS number 56211-40-6, is a new-generation long-acting and high-efficiency loop diuretic API. As an upgraded diuretic after furosemide and bumetanide, it has superior comprehensive pharmacological properties, high bioavailability, stable long-lasting efficacy and excellent safety. It is widely used in the treatment of cardiovascular diseases, kidney diseases and liver diseases, and has become a key raw material in global pharmaceutical research and standardized preparation production. With stable chemical structure, strict impurity control and pharmaceutical-grade purity that meets international pharmacopoeia standards, Torasemide can be processed into oral tablets, injections and other dosage forms, enjoying high recognition in the pharmaceutical industry.

In terms of pharmacological mechanism, Torasemide acts precisely on the thick ascending limb of the renal medullary loop and distal renal tubules. It specifically inhibits the activity of the Na-K-2Cl cotransporter, blocks the reabsorption of sodium, potassium and chloride ions, and greatly increases the excretion of water and electrolytes in urine, thereby rapidly eliminating water and sodium retention and achieving diuretic, detumescent and hypotensive effects. Compared with traditional loop diuretics, Torasemide has obvious core advantages. Its oral bioavailability exceeds 80% and is not affected by food intake, ensuring stable and efficient absorption in the human body. It has a longer half-life with the drug effect lasting 12 to 24 hours, which reduces medication frequency and avoids repeated symptoms caused by fluctuating drug efficacy. Moreover, it does not affect glomerular filtration rate and renal blood flow, causing no damage to renal function, so it is suitable for long-term medication of patients with renal insufficiency.

Clinically, Torasemide covers a wide range of treatment scenarios and is the preferred raw material for various edematous diseases and hypertension. For systemic edema and pulmonary edema caused by congestive heart failure, it can quickly reduce cardiac capacity load, improve cardiopulmonary circulation and myocardial blood supply, relieve clinical symptoms such as asthma and swelling, and reduce the risk of heart failure deterioration. For intractable renal edema caused by nephrotic syndrome, acute and chronic nephritis and renal damage, it maintains stable and reliable diuretic effect and effectively improves water and electrolyte metabolism disorders. It can also assist in treating hepatic edema and ascites caused by liver cirrhosis. In addition, it is a common auxiliary drug for primary hypertension, which stably regulates blood pressure by excreting excess water and sodium, suitable for long-term management of mild and moderate hypertension with excellent combined medication effect.

In terms of safety and industrial application, Torasemide has better tolerance than similar diuretics. Under conventional therapeutic doses, adverse reactions are mild with low incidence, only occasional slight electrolyte disorders and gastrointestinal discomfort, which can be relieved by dosage adjustment without obvious liver and kidney accumulation toxicity. Its mild and long-lasting diuretic effect avoids dehydration and sudden hypotension caused by excessive diuresis, ensuring higher clinical medication safety. At present, Torasemide adopts mature synthetic technology with stable quality and small batch difference, fully meeting the large-scale and standardized production needs of pharmaceutical enterprises. With the comprehensive advantages of long efficacy, high efficiency and high safety, Torasemide has gradually replaced traditional diuretics and become one of the most widely used loop diuretic APIs in global clinical treatment and new drug research, with huge market demand and broad development prospects.